Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results

Raba Thapa,1 Nhukesh Maharjan,2 Govinda Paudyal11Vitreo-retinal Service, Tilganga Institute of Ophthalmology, 2Research Department, Tilganga Institute of Ophthalmology, Kathmandu, NepalPurpose: The purpose of this study was to evaluate the long-term safety, anatomical, and visual outcomes following...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thapa R, Maharjan N, Paudyal G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/520b706664a74fc6a3ab4b182338a817
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:520b706664a74fc6a3ab4b182338a817
record_format	dspace
spelling	oai:doaj.org-article:520b706664a74fc6a3ab4b182338a8172021-12-02T08:55:45ZIntravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results1177-54671177-5483https://doaj.org/article/520b706664a74fc6a3ab4b182338a8172012-07-01T00:00:00Zhttp://www.dovepress.com/intravitreal-bevacizumab-in-macular-edema-secondary-to-branch-retinal--a10383https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Raba Thapa,1 Nhukesh Maharjan,2 Govinda Paudyal11Vitreo-retinal Service, Tilganga Institute of Ophthalmology, 2Research Department, Tilganga Institute of Ophthalmology, Kathmandu, NepalPurpose: The purpose of this study was to evaluate the long-term safety, anatomical, and visual outcomes following intravitreal bevacizumab (Avastin; Genentech) on macular edema (ME) secondary to branch retinal vein occlusion (BRVO).Methods: A prospective, interventional case series study was conducted among patients with ME due to BRVO, from June 2008 to October 2011. Intravitreal bevacizumab (1.25 mg/0.05 mL) was given at 4&ndash;6 weekly intervals until the ME subsided, and cases were followed up for a year. Complete ophthalmic evaluations and measurement of central retinal thickness (CRT) by optical coherence tomography were performed at baseline and follow-up visits.Results: Sixty-three eyes of 63 patients were included in the study. The mean age was 58.22 years (standard deviation [SD], 12.3). The CRT at baseline was 515.3 &plusmn; 189.4 &micro;m, and it significantly improved at each follow-up, with a CRT of 233.6 &plusmn; 101.5 &micro;m at 12 months. The best-corrected visual acuity (BCVA) at baseline was 0.82 &plusmn; 0.54, and it significantly improved at each follow-up, with a BCVA of 0.40 &plusmn; 0.25 at 12 months (P &lt; 0.001). The BCVA was better in 76% of the patients with a more than three-line increase in 55.5% of the eyes. The average number of intravitreal bevacizumab injections was 3.1 (range, 1&ndash;6 injections). Recurrent ME occurred in 30.2% of cases. There were no major ocular or systemic adverse events.Conclusion: Intravitreal bevacizumab appears to be a safe and effective drug for reducing ME and improving visual acuity secondary to BRVO at 12-month follow-up at a tertiary referral eye hospital in Nepal.Keywords: branch retinal vein occlusion, bevacizumab, macular edemaThapa RMaharjan NPaudyal GDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1057-1062 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Thapa R Maharjan N Paudyal G Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
description	Raba Thapa,1 Nhukesh Maharjan,2 Govinda Paudyal11Vitreo-retinal Service, Tilganga Institute of Ophthalmology, 2Research Department, Tilganga Institute of Ophthalmology, Kathmandu, NepalPurpose: The purpose of this study was to evaluate the long-term safety, anatomical, and visual outcomes following intravitreal bevacizumab (Avastin; Genentech) on macular edema (ME) secondary to branch retinal vein occlusion (BRVO).Methods: A prospective, interventional case series study was conducted among patients with ME due to BRVO, from June 2008 to October 2011. Intravitreal bevacizumab (1.25 mg/0.05 mL) was given at 4&ndash;6 weekly intervals until the ME subsided, and cases were followed up for a year. Complete ophthalmic evaluations and measurement of central retinal thickness (CRT) by optical coherence tomography were performed at baseline and follow-up visits.Results: Sixty-three eyes of 63 patients were included in the study. The mean age was 58.22 years (standard deviation [SD], 12.3). The CRT at baseline was 515.3 &plusmn; 189.4 &micro;m, and it significantly improved at each follow-up, with a CRT of 233.6 &plusmn; 101.5 &micro;m at 12 months. The best-corrected visual acuity (BCVA) at baseline was 0.82 &plusmn; 0.54, and it significantly improved at each follow-up, with a BCVA of 0.40 &plusmn; 0.25 at 12 months (P &lt; 0.001). The BCVA was better in 76% of the patients with a more than three-line increase in 55.5% of the eyes. The average number of intravitreal bevacizumab injections was 3.1 (range, 1&ndash;6 injections). Recurrent ME occurred in 30.2% of cases. There were no major ocular or systemic adverse events.Conclusion: Intravitreal bevacizumab appears to be a safe and effective drug for reducing ME and improving visual acuity secondary to BRVO at 12-month follow-up at a tertiary referral eye hospital in Nepal.Keywords: branch retinal vein occlusion, bevacizumab, macular edema
format	article
author	Thapa R Maharjan N Paudyal G
author_facet	Thapa R Maharjan N Paudyal G
author_sort	Thapa R
title	Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
title_short	Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
title_full	Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
title_fullStr	Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
title_full_unstemmed	Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
title_sort	intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/520b706664a74fc6a3ab4b182338a817
work_keys_str_mv	AT thapar intravitrealbevacizumabinmacularedemasecondarytobranchretinalveinocclusion12monthresults AT maharjann intravitrealbevacizumabinmacularedemasecondarytobranchretinalveinocclusion12monthresults AT paudyalg intravitrealbevacizumabinmacularedemasecondarytobranchretinalveinocclusion12monthresults
_version_	1718398301767729152

Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results

Ejemplares similares